Literature DB >> 31819218

Therapeutic targeting of the complement system.

Daniel Ricklin1, Dimitrios C Mastellos2, John D Lambris3.   

Abstract

Entities:  

Year:  2019        PMID： 31819218      PMCID： PMC7346643          DOI： 10.1038/s41573-019-0055-y

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

Review 1.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

Review 2.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

Review 3.  Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions.

Authors:  Faith H Brennan; John D Lee; Marc J Ruitenberg; Trent M Woodruff
Journal:  Semin Immunol       Date:  2016-04-03       Impact factor: 11.130

Review 4.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 5.  Protection of host cells by complement regulators.

Authors:  Christoph Q Schmidt; John D Lambris; Daniel Ricklin
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 6.  The renaissance of complement therapeutics.

Authors:  Daniel Ricklin; Dimitrios C Mastellos; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

Review 7.  Complement in disease: a defence system turning offensive.

Authors:  Daniel Ricklin; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2016-05-23       Impact factor: 28.314

Review 8.  Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Am J Kidney Dis       Date:  2015-05-29       Impact factor: 8.860

Review 9.  Complement Therapeutics in Autoimmune Disease.

Authors:  Joshua M Thurman; Roshini Yapa
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

Review 10.  The alternative complement pathway revisited.

Authors:  Morten Harboe; Tom Eirik Mollnes
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310
View more
  10 in total

Review 1.  Compstatins: the dawn of clinical C3-targeted complement inhibition.

Authors:  Christina Lamers; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Trends Pharmacol Sci       Date:  2022-01-25       Impact factor: 17.638

Review 2.  Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis.

Authors:  Sofie Vandendriessche; Seppe Cambier; Paul Proost; Pedro E Marques
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 3.  The Role of Complement in Angiogenesis.

Authors:  Maciej M Markiewski; Elizabeth Daugherity; Britney Reese; Magdalena Karbowniczek
Journal:  Antibodies (Basel)       Date:  2020-12-01

Review 4.  How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.

Authors:  Bo Nilsson; Barbro Persson; Oskar Eriksson; Karin Fromell; Michael Hultström; Robert Frithiof; Miklos Lipcsey; Markus Huber-Lang; Kristina N Ekdahl
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

5.  Fasciola hepatica is refractory to complement killing by preventing attachment of mannose binding lectin (MBL) and inhibiting MBL-associated serine proteases (MASPs) with serpins.

Authors:  Carolina De Marco Verissimo; Heather L Jewhurst; József Dobó; Péter Gál; John P Dalton; Krystyna Cwiklinski
Journal:  PLoS Pathog       Date:  2022-01-10       Impact factor: 6.823

6.  Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.

Authors:  Kelly C Fahnoe; Fei Liu; Jennifer G Morgan; Sarah T Ryan; Michael Storek; Ellen Garber Stark; Fred R Taylor; V Michael Holers; Joshua M Thurman; Stefan Wawersik; Susan L Kalled; Shelia M Violette
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

7.  Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.

Authors:  Philip F Stahel; Scott R Barnum
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

Review 8.  Recent advances in the treatment of osteoarthritis.

Authors:  Susanne Grässel; Dominique Muschter
Journal:  F1000Res       Date:  2020-05-04

9.  Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.

Authors:  Lin-Ping Wu; Mario Ficker; Jørn B Christensen; Dmitri Simberg; Panagiotis N Trohopoulos; Seyed M Moghimi
Journal:  Nat Commun       Date:  2021-08-11       Impact factor: 14.919

Review 10.  Tipping the balance: intricate roles of the complement system in disease and therapy.

Authors:  Richard B Pouw; Daniel Ricklin
Journal:  Semin Immunopathol       Date:  2021-10-26       Impact factor: 9.623
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.